Two Cases of Superior Limbic Keratoconjunctivitis Treated with Bevacizumab and Triamcinolone Injection.
10.3341/jkos.2014.55.3.443
- Author:
Won Soo KIM
1
;
Sung Wook WEE
;
Jae Chan KIM
Author Information
1. Department of Ophthalmology, Chung-Ang University College of Medicine, Seoul, Korea. jck50ey@kornet.net
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Superior limbic keratoconjunctivitis;
Triamcinolone
- MeSH:
Aged;
Female;
Humans;
Inflammation;
Keratoconjunctivitis*;
Middle Aged;
Ophthalmic Solutions;
Recurrence;
Triamcinolone*;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2014;55(3):443-448
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report two cases of intractable superior limbic keratoconjunctivitis (SLK) treated with bevacizumab and triamcinolone injection. CASE SUMMARY: A 69-year-old female visited our clinic with pain in the left eye for 3 days and was diagnosed with SLK in her left eye. After 3 months of using steroid eye drops, artificial tears, and oral steroid intermittently, there was no improvement in symptoms and signs, thus this case was considered intractable with the conventional therapy. A mixture of bevacizumab (0.15 cc) and triamcinolone (0.05 cc) was injected into the sub-tenon's capsule of the left eye. After 1 week, all symptoms and signs disappeared, and there was no recurrence for 6 months. A 55-year-old female was transferred to our clinic due to SLK that did not respond to artificial tears, steroid eye drops, punctal occlusion, and botox injection for 3 months. A mixture of bevacizumab (0.15 cc) and triamcinolone (0.05 cc) was injected into the sub-tenon's capsule of the left eye. After 2 weeks, all symptoms and signs were improved, and there was no recurrence for 4 months. CONCLUSIONS: The presented 2 SLK cases are meaningful, because neovascularization disappeared and controlled inflammation was obtained following sub-tenon injection with both bevacizumab and triamcinolone.
